Merck & Co. (MRK) valuation, revenue & earnings

P/E and P/S history, revenue and growth, ROIC vs. cost of capital, segments, earnings and analyst forecasts

At a glance

Market capitalisation$365B

Moat ratingNarrow moat

ValuationFair

Revenue, and where it comes from$65.0bn in 2025: Keytruda and Qlex $31.7bn (49%), other pharmaceutical $21.2bn, Animal Health $6.4bn, Gardasil $5.2bn

Recent years are exact, taken from company filings; the earliest years are approximate. Forecast figures are Wall Street consensus, not company guidance. Read the full Merck & Co. moat analysis →